Plasma-derived circulating tumor DNA (ctDNA) as a surrogate biomarker for treatment response with the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with LDAC or decitabine in acute myeloid leukemia (AML)

Category Primary study
JournalClinical Cancer Research
Year 2020
This article has no abstract
Epistemonikos ID: f71a5d67e400d7a7d93256151fcae19ecc396a9a
First added on: Feb 12, 2025